Dr. Turner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
# 320
Rochester, NY 14642Phone+1 585-275-2222Fax+1 585-273-1222
Education & Training
- University of RochesterResidency, Internal Medicine, 2012 - 2015
- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2013
Certifications & Licensure
- NY State Medical License 2015 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Start of enrollment: 2017 Sep 20
- Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma Start of enrollment: 2019 Jul 24
Roles: Contact
Publications & Presentations
PubMed
- 15 citationsHE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.Rachael B. Rowswell-Turner, Rakesh K. Singh, Anze Urh, Naohiro Yano, Kyu Kwang Kim
Journal of Immunology. 2021-04-26 - 19 citationsThe biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genesNicole E. James, Jenna B. Emerson, Ashley D. Borgstadt, Lindsey Beffa, Matthew T. Oliver
Scientific Reports. 2020-05-22 - 18 citationsRole of trypsin and protease-activated receptor-2 in ovarian cancer.Kyu Kwang Kim, Rachael Turner, Negar Khazan, Arif Kodza, Aaron Jones
Plos One. 2020-05-04
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: